Company news

Pharvaris N.V. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Pharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference

July 13, 2022

Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13

July 5, 2022

Pharvaris Participates in the Kinin 2022 Conference

June 6, 2022

Pharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day: -)

May 15, 2022

Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights

May 10, 2022

Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer

May 10, 2022

Pharvaris to Participate in BofA Securities 2022 Healthcare Conference

May 4, 2022

Pharvaris to Participate in Upcoming April Investor Conferences

April 5, 2022

Pharvaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

March 28, 2022

Pharvaris Announces Preclinical Pharmacological Data for Small Molecule PHA121 Published in International Immunopharmacology

March 21, 2022

Pharvaris to Participate in Upcoming March Investor Conferences

March 2, 2022

Pharvaris to Participate in 11th Annual SVB Leerink Global Healthcare Conference

February 8, 2022

Pharvaris Announces Changes to its Board of Directors

December 21, 2021

Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights

November 9, 2021

Pharvaris to Participate in Upcoming September Investor Conferences

September 2, 2021

Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights

July 29, 2021

Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021

July 9, 2021

Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021

June 30, 2021

Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE, at 12th C1 Inhibitor Deficiency and Angioedema Workshop

June 3, 2021

Pharvaris Reports First Quarter 2021 Financial Results and Provides Business Highlights

May 25, 2021

Pharvaris Appoints Wim Souverijns, Ph.D., as Chief Community Engagement & Commercial Officer

May 11, 2021

Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights

April 28, 2021

Pharvaris Announces FDA Acceptance of IND Application for Prophylactic Treatment of HAE Using PHVS416

April 20, 2021

Pharvaris to Participate in BioCapital Europe

March 3, 2021

Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE

February 25, 2021

Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting

February 18, 2021

Pharvaris Announces Closing of Initial Public Offering

February 8, 2021

Pharvaris Announces Pricing of Upsized Initial Public Offering

February 3, 2021

← Newer news releases

Decks

The 5 newest of 19 decks. Every deck is listed under its year.